Becton Dickinson Tops Estimates With Adjusted EPS of $4.15, Revenue of $5.27 Billion

Becton Dickinson (NYSE: BDX) reported fourth-quarter fiscal 2026 revenue of $5.27 billion, above the $5.11 billion analysts expected, and adjusted diluted EPS of $4.15 against the $4.07 average analyst estimate, according to an 8-K filed Thursday. Revenue rose 5.4% from a year earlier, or 5.6% on a currency-neutral basis.

GAAP diluted EPS from continuing operations was $2.52, up from $1.20 a year earlier. Net income was $696 million, or $2.54 per diluted share, including discontinued operations.

Segment and regional results

Medical Essentials revenue rose 5.9% to $1.79 billion. BioPharma Systems rose 6.5% to $748 million, and Interventional rose 7.6% to $1.47 billion. Connected Care grew 1.6% to $1.27 billion.

U.S. revenue increased 4.3% to $3.20 billion, while international revenue increased 7.0% to $2.07 billion.

Full-year results and guidance

For fiscal 2026, revenue was $19.5 billion, up 4.9% as reported. Adjusted diluted EPS was $12.70, and GAAP diluted EPS from continuing operations was $5.06. Cash from continuing operations rose 30.0% to $3.6 billion, and free cash flow rose 42.5% to $2.9 billion. The company repurchased $2.43 billion of common stock during the year.

BD guided fiscal 2027 to low single-digit GAAP and currency-neutral revenue growth and to adjusted diluted EPS of $13.10 to $13.30. The average analyst estimate for fiscal 2027 adjusted EPS was $13.30, at the top of that range. The company said its adjusted EPS guidance excludes items such as acquisition-related amortization and separation costs.

BD also said it will hold its 2026 Investor Day on Dec. 10 at the New York Stock Exchange.

BD's last close before the filing was $209.19 on Wednesday, Nov. 4, giving the company a market value of about $56.98 billion.